## Drug of Choice: Amlodipine **Key Point:** In stable angina with contraindication to beta-blockers, a calcium channel blocker (CCB) — specifically a dihydropyridine like amlodipine — is the preferred first-line agent. ### Why Amlodipine? 1. **Dual antianginal mechanism** - Coronary vasodilation → increased myocardial blood flow - Peripheral vasodilation → reduced afterload and myocardial oxygen demand 2. **Additional benefit in this patient** - Controls hypertension (BP reduction) - Reduces LV hypertrophy over time - Long half-life (35–50 hours) → once-daily dosing, better compliance 3. **No contraindication to beta-blocker intolerance** - CCBs work via a different mechanism (L-type calcium channel blockade) - Can be combined with nitrates if needed ### Comparison with Alternatives | Drug | Role in Stable Angina | Why Not First-Line Here | | --- | --- | --- | | **Amlodipine** | First-line (non-BB patient) | — | | **Isosorbide dinitrate** | Adjunctive or symptomatic relief | Tolerance develops with continuous use; not monotherapy for stable angina | | **Ivabradine** | Heart rate reduction in angina | Reserved for beta-blocker intolerance *with* elevated resting HR; not first-line | | **Ranolazine** | Late sodium channel inhibitor | Adjunctive agent; not first-line monotherapy | **Clinical Pearl:** Dihydropyridine CCBs (amlodipine, nifedipine) are preferred over non-dihydropyridines (verapamil, diltiazem) in angina because they do not slow AV conduction and have more potent vasodilation. **High-Yield:** In a beta-blocker intolerant patient with stable angina + hypertension + LVH, **amlodipine** addresses all three conditions and is guideline-recommended first-line. [cite:KD Tripathi 8e Ch 31]
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.